Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

Table 2 Distribution of patients in the study groups and among randomized treatments

	A (pre-treatment)		P (pre-treatment)		T (pre-treatment)		Total
	n	ER-α-positive	n	ER-α-positive	n	ER-α-positive	n	ER-α-positive
ER- β-negative	11	9	12	9	5	3	28	21
ER- β-positive	13	9	16	14	18	13	47	36
ER-α/ER-β ratio < 1	5	2	5	2	8	4	18	8
ER-α/ER-β ratio between 1 and 1.5	9	7	7	6	6	5	22	18
ER-α/ER-β ratio > 1.5	10	9	16	15	9	7	35	31

A: anastrozole group; P: placebo group; T: tamoxifen group.
ER-α-positive: number of patients in each group considered positive to ER-α (final Allred score equal to or greater than 3).

ISSN: 1471-2407